Molecular Analysis of Retinoblastoma
| Status: | Completed |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/21/2012 |
| Start Date: | April 2007 |
| End Date: | April 2013 |
| Contact: | Rachel Brennan, MD |
| Email: | info@stjude.org |
| Phone: | 1-866-278-5833 |
Retinoblastoma is a childhood tumor of the retina that affects approximately 1 in 18,000
children. Retinoblastoma is more prevalent in Central America, where most patients present
with advanced intraocular and extraocular disease. Therefore, we have formed collaboration
with Central American investigators to provide us with frozen retinoblastoma tumors from
patients undergoing routine enucleation. The objective of this protocol is to begin to
identify the mutations and gene expression changes that occur in retinoblastoma cells
following RB1 gene inactivation in order to more effectively target chemotherapy for
treating bilateral retinoblastoma.
This is a biology protocol with no treatment regimen associated. Following routine
enucleation of the retinoblastoma affected eye, a portion of the tumor will be removed and
flash frozen and sent to St. Jude for RNA and DNA analysis. Some tissue will undergo
histopathological analysis and tissue microarrays will be isolated.
Inclusion Criteria:
- Must have clinical diagnosis of retinoblastoma (to be confirmed histologically after
enucleation)
- Legal guardians must willing to sign an informed consent indicating that they are
aware of this study and its possible benefits. Legal guardians will be given a copy
of the consent form.
- Patient is being seen at this AHOPCA institution:
Exclusion Criteria:
- Ophthalmologist or oncologist is concerned that sampling will interfere with staging.
- Diagnosis other than retinoblastoma.
- Affiliated hospital is unable to provide pathologic evidence of retinoblastoma.
We found this trial at
1
site
Click here to add this to my saved trials
